Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Cincinnati, College of Medicine, Albert Sabin Way, Cincinnati, OH 45267-0526, USA.
Gynecol Oncol. 2011 Jan;120(1):152-7. doi: 10.1016/j.ygyno.2010.09.002. Epub 2010 Oct 14.
The aim is to present an overview of tumor markers other than CA-125 that have been proposed for use in the diagnosis of epithelial ovarian cancer and explore molecular studies which have been used to identify genomic and proteomic changes associated with this malignancy for possible future development of more sensitive tumor markers.
A Medline search was conducted to review published articles from American and European studies from 1990 to 2010, related to tumor markers for ovarian cancer. Different methods such as genomic, proteomic and transcriptional profiling were used to identify new tumor markers for clinical use.
A few of the newer tumor markers alone have demonstrated equal or slightly higher sensitivity to CA-125. Improved sensitivity and specificity have been reported using these new markers combined with CA-125.
Addition of new tumor markers as a compliment to CA-125 were associated with higher sensitivity and detection rates than either marker alone. However, the low prevalence of ovarian cancer necessitates a higher level of sensitivity and specificity that has still not been achieved if these biomarkers are used for diagnosis and monitoring the disease progress as a result of low positive predictive value.
本文旨在介绍除 CA-125 以外的其他肿瘤标志物在诊断上皮性卵巢癌中的应用，并探讨用于识别与这种恶性肿瘤相关的基因组和蛋白质组变化的分子研究，以期未来开发出更敏感的肿瘤标志物。
通过 Medline 检索，对 1990 年至 2010 年期间美国和欧洲发表的与卵巢癌肿瘤标志物相关的文章进行了综述。使用基因组学、蛋白质组学和转录组学等不同方法来识别新的用于临床的肿瘤标志物。
少数新的肿瘤标志物单独使用时，其敏感性与 CA-125 相当或略高。联合使用这些新标志物与 CA-125 可提高敏感性和特异性。
添加新的肿瘤标志物作为 CA-125 的补充与更高的敏感性和检测率相关，高于任一标志物单独使用的情况。然而，由于卵巢癌的低患病率，需要更高的敏感性和特异性，如果这些生物标志物用于诊断和监测疾病进展，由于阳性预测值较低，仍未达到这一要求。
